@entity2265 and @entity3528 are common complications of @entity454 ( @entity740 stage 5) that, when untreated, may result in increased morbidity and mortality. @entity2265 and @entity2741 have been associated with @entity453 . Achieving control of serum @entity3151 without increasing serum @entity460 is an important goal for @entity1 with @entity454 . Although @entity460 -based @entity1391 binders effectively reduce serum @entity3151 and @entity461 concentrations, these agents can lead to @entity2741 and have been associated with @entity729 . The @entity3151 binder sevelamer was developed to overcome the limitations associated with the usual management of @entity2265 and @entity3528 (i.e., mineral salts). Sevelamer, a nonabsorbable hydrogel, is as efficacious as @entity460 -based @entity1391 binders for reducing serum @entity3151 but does not cause @entity2741 or other adverse metabolic effects. Sevelamer also exhibits beneficial effects on lipids, consistently and significantly decreasing LDL @entity165 and increasing HDL @entity165 in most studies. In a head-to-head randomized clinical trial, sevelamer and @entity460 -based binders achieved similarly excellent @entity3151 control, but the use of @entity460 -based binders led to significantly higher serum @entity460 concentrations and an increased incidence of @entity2741 and unintended suppression of @entity461 . Treatment with @entity460 -based binders also led to the progression of coronary artery and @entity730 , whereas sevelamer attenuated or arrested progression. Strategies that use oral @entity460 and @entity560 in @entity1 with @entity454 should be reexamined, and the potential advantages of sevelamer should be considered when selecting a primary agent to reduce serum @entity3151 in hemodialysis @entity1 .

Slowing the progression of XXXX in hemodialysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary hyperparathyroidism'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus'] @entity730 :: ('MESH:D002114', 'Disease') :: ['aortic calcification'] @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia', 'Hyperphosphatemia'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity729 :: ('MESH:D061205', 'Disease') :: ['increased vascular calcification'] @entity453 :: ('MESH:D003324', 'Disease') :: ['increased coronary artery calcification'] @entity461 :: ('5741', 'Gene') :: ['parathyroid hormone'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD']
@entity729 :: (MESH:D061205,Disease) :: ['vascular calcification']
